The association between new cancer therapy innovations and financial toxicity
The trade-off between survival gains and increased economic hardships linked to treatment innovations underscores the need to expand our focus beyond clinical outcomes and implement protective measures that ensure healthcare advancements promote population health without inducing financial distress.
Authors
- Sara Khor (ORCID: https://orcid.org/0000-0003-0157-528X)
- Veena Shankaran (ORCID: https://orcid.org/0000-0001-8136-6140)
- Anirban Basu (ORCID: https://orcid.org/0000-0003-4238-7402)
- Catherine R. Fedorenko (ORCID: https://orcid.org/0000-0002-6478-0769)
- Scott David Ramsey (ORCID: https://orcid.org/0000-0001-5972-8280)
- Aasthaa Bansal (ORCID: https://orcid.org/0000-0001-5507-2640)
- Josh John Carlson (ORCID: https://orcid.org/0000-0001-7664-8370)
- Kaiyue Yu
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- University of Washington (US)
- University of Washington Medical Center (US)
- Fred Hutch Cancer Center (US)
- Stanford Health Care (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Seattle Indian Health Board (US)
- Stanford University (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1093/jnci/djaf152
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.13